Tilray projects $68M-$75M adjusted EBITDA in fiscal 2027 as it targets margin expansion
View original at seekingalpha.comTilray projects $68M-$75M adjusted EBITDA in fiscal 2027 as it targets margin expansion Earnings Call Insights: Tilray Brands, Inc. (TLRY) Q4 fiscal 2026 MANAGEMENT VIEW * "Fiscal 2026 proves something important and exciting…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
4Q organic growth, excluding BrewDog, was down 17%.
60% confidenceTilray is not a one-trick pony and is not waiting on U.S. cannabis rescheduling/legalization, which is not projected in its numbers.
60% confidenceInternational cannabis revenue was impacted by approximately $21.1 million of price compression, which largely flows through to gross profit and the bottom line.
60% confidenceTilray has plenty of cannabis supply and could be one of the lowest cost producers given its scale and size.
60% confidenceAdjusted EBITDA increased 11% to $61.1 million, impacted by approximately $2.3 million in unanticipated fuel surcharges.
60% confidenceOver time, Tilray aims to be a 15% to 18% EBITDA margin business.
60% confidenceTilray reduced debt by approximately $60 million, ending the year with net debt of less than $1 million; since April it raised $87 million of gross proceeds via ATM at an average price of $6.77 per share.
60% confidenceBeginning January 1, 2027, Tilray will brew, market and sell Carlsberg, Carlsberg Elephant 1664, and Kronenbourg 1664 Blanc across the U.S.
60% confidenceThe 4Q beverage decline excluding BrewDog was self-inflicted from skew rationalization and exiting unprofitable businesses; Shock Top and Carlsberg will be the two national brands, with the rest regional.
60% confidenceTilray would consider entering big U.S. states under a state-silo model where opportunities exist, but would need to weigh policy durability.
60% confidenceTilray ended fiscal 2026 with approximately $235 million in cash and marketable securities and near-breakeven net debt, plus nearly $700 million of operating assets.
60% confidenceThe integration and optimization of acquired beverage brands has taken longer than expected amid broader category headwinds.
60% confidenceIn the prior quarter, management reaffirmed fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million.
60% confidenceThe Canada adult-use volume/pricing shift was 90% driven by mix, with a small positive pricing contribution offset by international shipment declines and deprioritization of wholesale.
60% confidenceInternational cannabis growth is sustained by having supply, improved speed of permits, and demand growth, despite major European price compression this year.
60% confidenceNet loss improved significantly to $105.2 million or $1.09 per share; adjusted net income improved 87% to $12.2 million or $0.11 per share.
60% confidenceTilray is a diversified global consumer products and pharmaceutical distribution company with leadership positions across cannabis, beverage, hospitality and wellness.
60% confidenceFiscal 2026 proves Tilray Brands is more than the company many people think it is.
60% confidenceNet revenue increased 11% in fiscal 2026 to a record $915.5 million, and net cannabis revenue increased 8% to $268.3 million.
60% confidenceFull vertical integration on the medical side ensures consistent grow, quality, and avoids buying in a spot market; Tilray has doctors and pharmacy staff.
60% confidenceFiscal 2026 delivered record revenue of over $915 million on an annualized pro forma basis and record adjusted EBITDA of $61.1 million ($63.4 million excluding fuel surcharges).
60% confidenceTilray is providing fiscal 2027 guidance of adjusted EBITDA between $68 and $75 million, a double-digit increase from fiscal 2026.
60% confidenceNobody has figured out U.S. cannabis rescheduling yet, and Tilray will be disciplined about M&A rather than jumping in.
60% confidenceEBITDA seasonality has quarters 1, 2 and 3 being roughly half the year combined, with quarter 4 being the other half.
60% confidenceVeterans Affairs reimbursement changes are calculated to have a $4 million a year impact on revenue in fiscal 2027.
60% confidenceCC Pharma's margin improvement reflects portfolio management, and Tilray is working toward compounding and a direct-to-consumer model in Germany.
60% confidenceTilray entered fiscal 2027 with priorities to expand margins, improve efficiency, accelerate innovation, and convert scale into stronger earnings power.
60% confidenceFourth quarter total net revenue increased 25% to $281.7 million and adjusted EBITDA increased 15% to a record $31.9 million.
60% confidenceTilray acquired an over $200 million annual revenue business for approximately $54 million and invested nearly $50 million of additional working capital.
60% confidence